Injectable treatment before surgery for advanced melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether an injected medicine placed directly into melanoma tumors before surgery can improve outcomes for melanoma that has spread to nearby lymph nodes/skin but can still be fully removed. It aims to shrink the cancer and reduce the chance it comes back after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have melanoma confirmed by biopsy or cell test, in stage IIIB, IIIC, or IIID, and all visible tumor deposits can be fully removed by surgery.
- You have a measurable tumor lesion that a doctor can inject (skin, under the skin, or a lymph node), with enough size to measure (at least 10 mm total longest diameter).
- You are 18 years or older and can have the study visits and blood tests as planned.
- Your overall health is good enough for treatment: you have limited symptom impact (ECOG/WHO score 0–1) and enough blood counts (white cells, hemoglobin, and platelets).
- Your main organ tests are acceptable (liver, kidney, and LDH levels), and you have screened negative for HIV, hepatitis B, and hepatitis C (with specific extra rules for hepatitis B past exposure).
- You are not pregnant or breastfeeding, and you can use reliable birth control during the study and for a few months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests Daromun, an injected treatment for advanced melanoma that has not responded to immunotherapy or cannot use it. It looks at how safe and effective Daromun is when given directly into skin tumors.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This study looks at how well immunotherapy works before surgery for melanoma that has spread. If you have stage III or IV melanoma that can be removed, you may be able to join this trial.
This trial tests two immunotherapy drugs, ipilimumab and nivolumab, given before surgery for people whose melanoma has come back after previous anti-PD1 treatment. The goal is to see if this combination can shrink the tumor and help prevent future recurrence.
This study tests whether giving two immunotherapy drugs (fianlimab and cemiplimab) before surgery helps treat melanoma that has spread to nearby lymph nodes or a small number of other sites. The goal is to shrink tumors and improve surgical outcomes.
Hear when a new Melanoma Stage IIIB trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.